IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, Rozzano, 20089 Milan, Italy.
School of Biomedical Engineering and Imaging Sciences-Faculty of Life Sciences and Medicine, King's College London, Westminster Bridge Rd, London SE1 7EH, England, United Kingdom.
Int J Cardiol. 2024 Oct 15;413:132390. doi: 10.1016/j.ijcard.2024.132390. Epub 2024 Jul 25.
Right ventricular (RV) involvement has been reported in one out of three patients with hypertrophic cardiomyopathy (HCM), however its prognostic significance remains unknown. We aimed to assess the prognostic value of RV involvement in patients with HCM through a systematic review and meta-analysis.
A literature search was performed on PubMed, ClinicalTrials.gov and Cochrane Library databases from inception through November 15, 2023. Original articles enrolling HCM patients >18 years old and evaluating the association of RV parameters routinely assessed in clinical practice through trans-thoracic echocardiography or cardiac magnetic resonance (i.e., RV hypertrophy, volumes, systolic function, and late gadolinium enhancement) and the risk of a pre-defined composite endpoint including i) all cause death; ii) cardiac death; iii) heart transplantation; iv) heart failure-related hospitalization; v) atrial fibrillation; vi) ventricular tachycardia; and vii) stroke were retrieved. We pooled the effect of RV imaging variables on the combined clinical endpoint in terms of hazard ratio (HR) with 95% confidence interval (CI).
The meta-analysis included 12 articles and 4634 patients. The pooled analysis demonstrated that the presence of RV systolic dysfunction conveyed an increased risk of adverse outcomes (HR 2.46; 95% CI 1.80-3.35; P < 0.001), whereas other RV imaging parameters were not significantly associated with patients' prognosis, except for RV-fractional area change analyzed as a continuous variable (HR 0.96 per % increase; 95% CI 0.93-0.995; P = 0.025).
Our results pinpoint a prognostic role of RV dysfunction, independent of left ventricular involvement, in patients with HCM, and future longitudinal studies, including multi-parametric RV assessment, are encouraged to provide clinically-relevant data to refine risk stratification in patients with HCM.
肥厚型心肌病(HCM)患者中有三分之一会出现右心室(RV)受累,但 RV 受累的预后意义尚不清楚。我们旨在通过系统回顾和荟萃分析评估 RV 受累在 HCM 患者中的预后价值。
我们对 PubMed、ClinicalTrials.gov 和 Cochrane Library 数据库进行了文献检索,检索时间截至 2023 年 11 月 15 日。纳入研究对象为年龄大于 18 岁的 HCM 患者,评估通过经胸超声心动图或心脏磁共振常规评估的 RV 参数(即 RV 肥厚、容积、收缩功能和钆延迟增强)与预先定义的复合终点(包括 i)全因死亡;ii)心脏死亡;iii)心脏移植;iv)心力衰竭相关住院;v)心房颤动;vi)室性心动过速;和 vii)中风)的风险之间的相关性。我们将 RV 影像学变量对联合临床终点的影响以危险比(HR)及其 95%置信区间(CI)进行汇总。
荟萃分析纳入了 12 篇文章和 4634 名患者。汇总分析显示,RV 收缩功能障碍与不良结局风险增加相关(HR 2.46;95% CI 1.80-3.35;P<0.001),而其他 RV 影像学参数与患者预后无显著相关性,除了 RV 分数面积变化作为连续变量进行分析时(HR 每增加 1%为 0.96;95% CI 0.93-0.995;P=0.025)。
我们的研究结果表明,RV 功能障碍与左心室受累无关,在 HCM 患者中具有预后作用,未来的纵向研究,包括多参数 RV 评估,有望提供有临床意义的数据,以细化 HCM 患者的风险分层。